FO
PRTK

FT Options’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

FT Options’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$4K Buy
+7,800
New +$182K 0.01% 203
2017
Q2 		– Sell
-27,500
Closed -$55K – 303
2017
Q1 		$55K Buy
+27,500
New +$433K 0.07% 145

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

FT Options's PRTK Position: Q3 2017 in Review

FT Options opened a new position in Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2017: 2,748 shares worth $69K. The stake represents 0.1% of the portfolio and ranks #113 among its holdings. This is a return to the name: FT Options previously reported a position in PRTK as recently as Q2 2016.

FT Options first reported a position in PRTK in Q2 2016 and has held it in 2 quarters since. The position peaked at $139K in Q2 2016. 133 funds tracked by Wall St. Rank hold PRTK as of Q3 2017.

  • FT Options held 2,748 shares of Paratek Pharmaceuticals, Inc. worth $69K as of Q3 2017.
  • Paratek Pharmaceuticals, Inc. was a new FT Options position in Q3 2017.
  • Paratek Pharmaceuticals, Inc. made up 0.1% of FT Options's portfolio in Q3 2017, its #113 holding.
  • FT Options first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2016 and has held it in 2 quarters since.
  • FT Options's Paratek Pharmaceuticals, Inc. position peaked at $139K in Q2 2016.
  • 133 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.